SCA
TVTX icon

Signpost Capital Advisors’s Travere Therapeutics TVTX Stock Holding History

Signpost Capital Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$1.55M Sell
84,111
-79,630
-49% -$1.56M 4.54% 6
2016
Q4 		$3.1M Sell
163,741
-39,400
-19% -$806K 3.8% 8
2016
Q3 		$4.55M Buy
+203,141
New +$3.87M 3.82% 9

Other funds holding TVTX

SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Signpost Capital Advisors's TVTX Position: Q1 2017 in Review

Signpost Capital Advisors reduced its Travere Therapeutics (TVTX) stake by 49% in Q1 2017, selling an estimated $1.56M and leaving 84,111 shares worth $1.55M. The position accounts for 4.54% of the portfolio, ranked #6.

Signpost Capital Advisors first reported a position in TVTX in Q3 2016 and has held it in 3 quarters since. The position peaked at $4.55M in Q3 2016. 114 funds tracked by Wall St. Rank hold TVTX as of Q1 2017.

  • Signpost Capital Advisors held 84,111 shares of Travere Therapeutics worth $1.55M as of Q1 2017.
  • Signpost Capital Advisors sold 79,630 Travere Therapeutics shares in Q1 2017, an estimated $1.56M.
  • Travere Therapeutics made up 4.54% of Signpost Capital Advisors's portfolio in Q1 2017, its #6 holding.
  • Signpost Capital Advisors first reported a position in Travere Therapeutics in Q3 2016 and has held it in 3 quarters since.
  • Signpost Capital Advisors's Travere Therapeutics position peaked at $4.55M in Q3 2016.
  • 114 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2017.

Based on Signpost Capital Advisors's 13F filing for Q1 2017, filed 1 May 2017.